Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock

$14.36

0.14% today

NYSE, Apr 08, 03:50 pm CET

ISIN

US8740602052

Symbol

TAK

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock price

$14.38

-1.47 9.27% 5Y

NYSE, Closing price Mon, Apr 07 2025

-0.34 2.31%

ISIN

US8740602052

Symbol

TAK

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$45.59b
Enterprise Value	$73.25b
P/E (TTM) P/E ratio	33.26
EV/FCF (TTM) EV/FCF	12.94
EV/Sales (TTM) EV/Sales	2.42
P/S ratio (TTM) P/S ratio	1.51
P/B ratio (TTM) P/B ratio	0.97
Dividend yield	4.25%
Last dividend (FY24)	$0.61
Revenue growth (TTM) Revenue growth	1.92%
Revenue (TTM) Revenue	$30.22b
EBIT (operating result TTM) EBIT	$4.07b
Free Cash Flow (TTM) Free Cash Flow	$5.66b
Cash position	$3.14b
EPS (TTM) EPS	$0.43
P/E forward	48.17
P/S forward	1.49
EV/Sales forward	2.39
Short interest	0.14%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

16 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

10x Buy

63%

6x Hold

38%

More details on Analyst Estimates Including Price Targets

16 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

Buy

63%

Hold

38%

Analyst Estimates with Stock Price Targets

Financial data from Takeda Pharmaceutical Co. Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	30,218 30,218	2% 2% 100%
- Direct Costs	14,223 14,223	1% 1% 47%
Gross Profit	15,995 15,995	3% 3% 53%
- Selling and Administrative Expenses	2,220 2,220	17% 17% 7%
- Research and Development Expense	4,694 4,694	5% 5% 16%
EBITDA	9,082 9,082	5% 5% 30%
- Depreciation and Amortization	5,008 5,008	7% 7% 17%
EBIT (Operating Income) EBIT	4,074 4,074	24% 24% 13%
Net Profit	1,364 1,364	8% 8% 5%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock News

Neutral

Accesswire

●

about 3 hours ago

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million USD milestone payment, following Takeda's (TSE:4502/NYSE:TAK) initiation of Phase 3 clinical ...

Positive

Seeking Alpha

●

7 days ago

Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns

Takeda's AI-powered "returning to growth" program has improved profit margins, leading to upgraded FY2024 guidance and a JPY100 billion share buyback program. Takeda's Rusfertide and Protagonist's Icotrokinra show strong Phase III results, with potential regulatory approvals and launches by 2026, boosting revenue prospects. Protagonist's financial stability, with a cash runway until 2028, suppo...

Neutral

Seeking Alpha

●

26 days ago

Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds

Japan-based Takeda Pharmaceutical, which has its ADR listed on the NYSE, gets a buy rating today, agreeing with the analyst consensus. Besides a diverse drug portfolio across multiple segments, they have a robust drug discovery pipeline to meet future clinical demand. The firm has been a proven cash flow generator, with an above-average dividend yield above +4%, and modest leverage risk.

More Takeda Pharmaceutical Co. Ltd. Sponsored ADR News

Company Profile

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Head office	Japan
CEO	Christophe Weber
Employees	49,281
Founded	1781
Website	www.takeda.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now